The NHS England has announced the routine commissioning of Daiichi Sankyo's quizartinib for acute myeloid leukaemia (AML).

The European Medicines Agency's Committee for Medicinal Products for Human Use has recommended an update to Novo Nordisk’s ...

The Outsourcing in Clinical Trials New England conference will gather pharma experts to discuss the current clinical trial ...

Optima Pharma has announced it will be exploring key trends and issues in the pharmaceutical industry in its series of expert ...

Ossium Health is also running the PRESERVE I trial to evaluate the safety and effectiveness of its deep-frozen bone marrow ...

NanoVation will receive $600m in upfront cash and potential milestone payments, as well as tiered royalties on future product ...

Before the FDA approved AstraZeneca’s Fasenra, Nucala was the only therapy for treating eosinophilic granulomatosis with ...

Statistics show incidences of cancer are rising in younger demographics. Tailored therapies offer a solution - if clinical ...

As part of the acquisition, Organon will acquire psoriasis treatment Vtama, which could soon be approved in atopic dermatitis ...

Lupin has announced a non-exclusive patent licence agreement with Takeda for the commercialisation of Vonoprazan Tablets in ...

Accord BioPharma received FDA approval for 420mg HERCESSI, a biosimilar to Herceptin to treat various kinds of ...